Guselkumab is the first IL-23 inhibitor approved by the FDA in 2017 for the treatment of moderate to severe plaque psoriasis,475 and its clinical effect has been demonstrated in different types of psoriasis.476–478 VOYAGE 1/2 is the first phase III clinical trial to investigate guselkumab in the treatment of patients with psoriasis; in this study, patients were randomized to receiving placebo, adalimumab, or guselkumab at 100 mg in week 0, week 4, and once every 8 weeks thereafter. Here, IL37 is linked to psoriasis vulgaris.